Small fiber neuropathy (SFN) damages the thin, unmyelinated nerve fibers that carry pain signals and regulate involuntary functions throughout the body, and the eyes are among the organs hit hardest. The cornea alone is one of the most densely nerve-packed tissues in the human body, and roughly 80% of those corneal nerves are the same small C fibers that SFN targets elsewhere. The result is a cluster of eye problems that ranges from chronic corneal pain and stubborn dry eye to abnormal pupil responses and light sensitivity, symptoms that often get misdiagnosed or dismissed because standard eye exams look normal.
Why the Cornea Is Ground Zero
The cornea, the clear dome at the front of your eye, contains a remarkably dense network of sensory nerves. About 80% of those fibers are slow-conducting, unmyelinated C fibers, with the remaining roughly 20% being thinly myelinated Aδ fibers. Both types fall under the “small fiber” umbrella. That means the cornea is essentially a small-fiber-rich tissue sitting right on the surface of the body, accessible for examination and highly vulnerable to the same disease process that causes burning feet and tingling hands in SFN patients.
When SFN causes nerve fibers to degenerate in the skin of the legs, the same degeneration can happen in the cornea. The nerve fibers shorten, thin out, and lose their normal branching pattern. In some cases, damaged nerve endings form tiny bulb-like structures called microneuromas, swollen stumps of injured nerves that can generate spontaneous pain signals. Researchers studying neuropathic corneal pain have found that patients show decreased corneal nerve fiber density, shorter nerve fiber length, and significantly more microneuromas compared to healthy eyes. Their tear fluid also contains elevated levels of nerve growth factor and neurofilament light polypeptide, proteins that signal active nerve injury and attempted repair.
Neuropathic Corneal Pain
The most distressing eye symptom for many SFN patients is chronic corneal pain that has no visible cause. Your eye burns, stings, or aches, sometimes constantly. An ophthalmologist examines you and sees a cornea that looks perfectly clear and healthy under the slit lamp. This disconnect between severe symptoms and a normal-looking eye is the hallmark of neuropathic corneal pain.
A 2024 study that analyzed tear proteins in neuropathic corneal pain patients found 188 significantly altered proteins in their tears compared to healthy controls. The biological pathways those proteins mapped to included neurotoxicity, axonal signaling, apoptosis (programmed cell death), and mitochondrial dysfunction, essentially a biochemical portrait of nerves under siege. Patients had reduced corneal sensitivity on clinical testing, shorter and less dense corneal nerve fibers, and a striking increase in microneuromas.
Researchers have also been working to distinguish neuropathic corneal pain from ordinary dry eye disease at the molecular level. A study published in The Ocular Surface identified 129 proteins that differed between the two conditions. Neuropathic corneal pain patients had elevated vinculin (a protein involved in cell adhesion and nerve structure) while dry eye patients had elevated inflammatory markers like S100A12 and matrix metallopeptidase 9. The microneuroma measurements alone, combined with pain questionnaire scores, achieved high diagnostic accuracy for separating the two conditions.
The Dry Eye Confusion
One of the most common ways SFN shows up in eye clinics is as dry eye disease that refuses to get better. Patients complain of grittiness, burning, and fluctuating vision. They get prescribed artificial tears, anti-inflammatory drops, and punctal plugs, and nothing works well enough. The reason is that the problem isn’t primarily on the eye’s surface. It’s in the nerves.
A 2025 study published in Cornea looked specifically at SFN symptoms in dry eye patients and found that the severity of systemic SFN symptoms correlated with dry eye symptoms and ocular pain but did not correlate with the objective clinical signs that eye doctors typically measure, like tear breakup time, tear production on Schirmer testing, or corneal sensitivity testing. Despite receiving standard dry eye treatments and showing stable clinical signs, most patients with severe SFN symptoms reported their dry eye getting worse over time. That pattern, worsening symptoms with stable or improving clinical measurements, is a red flag that neuropathic mechanisms are driving the problem.
There is also a genuine overlap. The autonomic small fibers that regulate tear production can themselves be damaged in SFN, leading to actual reduced tear output. Animal research has shown that the sympathetic nervous system controls lacrimal gland tear secretion through a noradrenaline signaling pathway. When the postganglionic nerves supplying the lacrimal gland are disrupted, tear secretion drops immediately and chronically, eventually leading to gland atrophy. So an SFN patient can simultaneously have true dry eye from autonomic nerve damage to the tear glands and neuropathic pain from sensory nerve damage in the cornea, a combination that is especially hard to untangle clinically.
Pupil Problems and Autonomic Effects
The pupil is controlled by autonomic small fibers, and when those fibers malfunction, the pupil does too. Fabry disease, a genetic condition that causes prominent small fiber neuropathy, provides a clear example. A study of Fabry disease patients found significant reductions in the amplitude of pupil contraction, the duration of contraction, and the latency of pupil dilation compared to healthy controls. The severity of these pupil abnormalities tracked with the severity of patients’ autonomic symptoms overall.
For patients, this can manifest as difficulty adjusting to changes in lighting, increased glare sensitivity, or a vague sense that vision is “off” in bright or dim environments. These pupil issues are distinct from the light sensitivity caused by corneal nerve damage (discussed below) but can layer on top of it, compounding visual discomfort.
Light Sensitivity and the Trigeminal Connection
Many SFN patients report that bright light is painful, not just uncomfortable. Research has identified a neural reflex circuit in which bright light activates nociceptive (pain-signaling) neurons in the trigeminal nucleus, the brainstem region that processes sensation from the face and eyes. In people with healthy corneal nerves, this pathway operates at a high threshold, so ordinary indoor lighting doesn’t trigger it. But when corneal small fibers are damaged and sending aberrant signals, the threshold can drop. The brain interprets normal light levels as painful, a phenomenon called photoallodynia.
This is separate from the photophobia you experience with, say, a migraine or an eye infection. Those involve inflammation or vascular mechanisms. SFN-related light pain stems from the peripheral nerve damage itself, which is why it can persist even when there is no active inflammation and why anti-inflammatory treatments don’t reliably help.
The Conditions That Drive Ocular Small Fiber Damage
SFN has dozens of known causes, and several of the most common ones produce particularly prominent eye involvement.
Diabetes
Diabetes is the single most studied cause of small fiber damage in the cornea. A cross-sectional study of people with type 2 diabetes found that autonomic neuropathy was present in about two-thirds of participants and peripheral neuropathy in more than half. Corneal nerve measurements worsened with longer diabetes duration and higher blood sugar levels, and patients who had diabetic retinopathy showed significantly reduced corneal nerve fiber density and length compared to those without retinopathy. This suggests that the same metabolic damage hitting the retinal blood vessels is simultaneously degrading the corneal nerves, though through different mechanisms.
Corneal confocal microscopy in diabetic patients can detect small fiber damage before patients develop symptoms or before standard nerve conduction studies show anything abnormal. That early-detection capability has made the diabetic eye a major research focus for preventing neuropathy progression.
Sjögren’s Disease
Sjögren’s disease, an autoimmune condition that attacks moisture-producing glands, is notorious for causing dry eyes. But a pilot study comparing corneal nerves in Sjögren’s patients to healthy controls found that the nerve damage goes far beyond what dryness alone would explain. Mean corneal nerve fiber density in Sjögren’s participants was about 3.5 per square millimeter compared to 10.6 in healthy controls, a roughly threefold reduction. Most strikingly, 16 of 22 Sjögren’s eyes examined had no identifiable central corneal whorl, a distinct spiral pattern of nerve fibers that was present in 21 of 22 control eyes. Losing that nerve architecture points to severe small fiber destruction, not just surface dryness.
When Sjögren’s patients also have confirmed SFN, the corneal damage appears even worse. A confocal microscopy study found significantly more microneuromas in Sjögren’s patients with SFN than in those without SFN, suggesting that the autoimmune process and the neuropathy compound each other’s damage to the corneal nerves.
Fibromyalgia
Fibromyalgia has been increasingly recognized as involving small fiber pathology, and the eyes are part of the picture. One study detected corneal small fiber abnormalities in 51% of fibromyalgia patients, with nearly half showing significantly decreased nerve fiber length compared to age- and sex-matched reference values. Another study found that fibromyalgia patients had thinner corneal stromal nerves and reduced sub-basal plexus nerve density compared to controls. Reductions in corneal nerve density and length correlated with patients’ ocular and visual symptoms, providing objective evidence that fibromyalgia-related eye complaints aren’t imagined.
Chemotherapy
Chemotherapy-induced peripheral neuropathy is a well-known side effect of several drug classes, and the corneal nerves are not spared. Because nerve fibers have high metabolic demands, they are particularly vulnerable to the toxic effects of chemotherapy agents. Confocal microscopy studies have documented corneal nerve damage in cancer patients undergoing treatment, adding eye symptoms to the already long list of chemotherapy side effects patients need to watch for.
Hereditary Sensory and Autonomic Neuropathy
At the extreme end, genetic conditions that cause severe small fiber loss can virtually eliminate corneal nerves. A confocal microscopy study of patients with hereditary sensory and autonomic neuropathy found that nerve bundles were clearly visible in healthy corneas but were undetectable in the central cornea of affected patients. Their corneal sensation was profoundly reduced, in some cases nearly 90 times less sensitive than normal. These patients are at high risk for corneal injuries they cannot feel, which can lead to infections and scarring if not monitored carefully.
Diagnosing SFN Through the Eye
Corneal confocal microscopy (CCM) has emerged as one of the most promising diagnostic tools for SFN, and it works by turning the eye into a window onto the body’s small fiber health. The technique uses a specialized microscope to photograph the corneal nerve layer in real time. It is rapid, non-invasive, and painless, essentially a very detailed eye scan that takes a few minutes.
The traditional gold standard for diagnosing SFN is a skin punch biopsy, usually taken from the ankle, in which pathologists count the density of small nerve fibers in the skin sample. CCM offers a compelling alternative. Studies have found that it has comparable diagnostic ability to skin biopsy for diabetic neuropathy, fibromyalgia, and amyloid neuropathy, and it may actually be better at detecting nerve regeneration over time because the same spot can be re-imaged repeatedly without cutting tissue. A review concluded that CCM meets the criteria for a surrogate endpoint in clinical trials for peripheral and central neurodegenerative diseases.
There are limitations. One study comparing CCM results to skin biopsy findings in patients with chronic idiopathic axonal polyneuropathy found that the two measures did not correlate in that specific patient group, even though they do correlate in diabetic neuropathy. This suggests that the relationship between corneal nerve damage and skin nerve damage may vary depending on the underlying cause of the neuropathy, something clinicians need to keep in mind when interpreting results.
Artificial intelligence is accelerating the field. Deep learning algorithms applied to corneal nerve images have demonstrated performance comparable to manual expert analysis and superior to older automated software for quantifying nerve fiber length, branching, and other metrics. One AI model trained to classify patients as healthy, neuropathic, or non-neuropathic achieved an area under the curve of 0.83 with high specificity. As these tools mature, they could make CCM-based SFN screening practical in general ophthalmology clinics, not just specialized research centers.
Treatment Approaches
Managing the ocular effects of SFN typically requires a two-pronged approach: treating the eye symptoms locally and addressing the underlying systemic neuropathy.
On the local side, autologous serum tears, eye drops made from a patient’s own blood serum, have shown the most consistent results for neuropathic corneal pain. In a study of patients treated with autologous serum tears for an average of about four months, pain severity dropped significantly, and confocal microscopy showed improvements in nerve fiber length, number, and overall health. The rationale is that blood serum contains nerve growth factors and other proteins that help damaged nerves repair themselves, something conventional artificial tears cannot provide. Topical nerve growth factor, already approved for a related condition called neurotrophic keratitis, is another emerging option for promoting corneal nerve healing.
For systemic pain management, medications originally developed for other forms of neuropathic pain are commonly used. Gabapentin, for instance, has shown benefit for chronic neuropathic pain conditions in large reviews, and clinicians have applied it to neuropathic ocular pain with the rationale that the pain mechanism is the same regardless of where the damaged nerves are located. Low-dose tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors are other common choices, though evidence specific to neuropathic eye pain is limited compared to general neuropathic pain data.
Treating the underlying cause, when one can be identified, remains the most effective long-term strategy. Tighter blood sugar control in diabetes, immunotherapy for autoimmune neuropathies, and removing offending medications in drug-induced cases can all slow or halt the nerve damage driving eye symptoms.
Can Corneal Nerves Regenerate?
One of the more encouraging aspects of corneal small fiber involvement is that these nerves can grow back, and CCM can track that recovery in real time. In a study of type 1 diabetes patients who received simultaneous pancreas and kidney transplants, corneal nerve fiber density increased significantly over 36 months compared to a control group of diabetic neuropathy patients whose nerves stayed the same. The transplant effectively normalized blood sugar, and the corneal nerves responded by regenerating.
Even newer medications may have regenerative effects. A case report described substantial improvement in corneal nerve fiber density, branch density, and fiber length in a diabetic patient after starting semaglutide, a GLP-1 receptor agonist primarily used for blood sugar and weight management. Large fiber nerve measures remained unchanged, suggesting the drug may have specific effects on small fibers. This is a single case, so it is far too early to draw broad conclusions, but it illustrates how the eye can serve as a real-time readout of whether a treatment is helping the body’s small nerves recover.
Researchers have also found that measuring corneal nerve fiber size, not just count and length, adds diagnostic and monitoring value. In a study of patients with diabetic neuropathy and sarcoidosis-associated SFN, changes in nerve fiber size helped track therapeutic response to cibinetide, an experimental nerve-repair agent. The ability to repeatedly image the same nerves without a biopsy makes the cornea uniquely suited for monitoring treatment trials.
Refractive Surgery as a Risk Factor
LASIK and similar refractive surgeries intentionally cut through corneal nerves to reshape the cornea, and for most people those nerves regrow within months. But a subset of patients develops chronic neuropathic corneal pain afterward. A study examining outcomes after both LASIK and SMILE (a newer, less invasive procedure) found neuropathic corneal pain in about 10-13% of patients. In LASIK specifically, eyes that developed neuropathic pain had lower preoperative corneal nerve fiber density and length, suggesting that people who start with fewer or thinner corneal nerves may be more vulnerable.
Confocal microscopy of post-LASIK neuropathic pain patients shows a now-familiar pattern: decreased nerve density, increased nerve beading, and microneuromas at the flap edge. Their tears show elevated nerve growth factor and calcitonin gene-related peptide, the same pain-signaling molecule involved in migraine. For someone who already has SFN or is at risk for it, these findings raise a practical question about whether refractive surgery is worth the added risk to already-compromised corneal nerves. The research doesn’t provide a clean cutoff for who should avoid surgery, but the finding that lower preoperative nerve density predicts postoperative pain is something both patients and surgeons should factor into the decision.
People with existing SFN who are considering refractive surgery might benefit from preoperative CCM to assess their baseline corneal nerve status. If nerve density is already low, the risk-benefit calculus may shift toward glasses or contact lenses rather than a procedure that temporarily eliminates whatever nerve supply remains.